Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln

Ocugen

01/08/2025 13:35

Overview

Ocugen Q2 revenue beats analyst expectations, reaching $1.37 mln

Company initiates dosing in OCU410ST Phase 2/3 GARDian3 trial

Ocugen announces reverse merger with OrthoCellix to focus on regenerative therapies

Outlook

Ocugen aims for 2026 BLA filings for OCU400 and OCU410ST

Ocugen progressing with OCU410ST Phase 2/3 trial for Stargardt disease

Proposed merger with OrthoCellix to focus on regenerative cell therapies

Result Drivers

CLINICAL TRIAL ADVANCEMENT - Ocugen is actively dosing patients in late-stage trials for OCU400 and OCU410ST

STRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.37 mln
$350,000 (4 Analysts)
Q2 EPS
-$0.05
Q2 Net Income
-$14.74 mln
Q2 Operating Expenses
$15.17 mln
Q2 Profit From Operations
-$13.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ocugen Inc is $7.00, about 85.3% above its July 31 closing price of $1.03

Press Release: ID:nGNX403Df3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)